BAGSVAERD, DENMARK--(Marketwired - July 01, 2013) - In continuation of the company's
announcements dated 31 January 2013 and 3 May 2013 concerning planned share
repurchase programmes, and pursuant to Section 204.25 of the New York Stock
Exchange Listed Company Manual, this is to report that Novo Nordisk A/S
(NYSE: NVO) and its wholly-owned affiliates on 30 June 2013 owned
14,976,660 of its own B shares of DKK 1, corresponding to a total nominal
value of DKK 14,976,660 or 2.7% of the total share capital.
In the second quarter of 2013 a total of 5,400,500 B shares were
repurchased, and 82,169 B shares were disposed of to employees in
connection with employee incentive programmes.
Novo Nordisk is a global healthcare company with 90 years of innovation and
leadership in diabetes care. The company also has leading positions within
haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 35,000
employees in 75 countries, and markets its products in more than 180
countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen
(Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For
more information, visit novonordisk.com.
Company Announcement No 48 / 2013:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novo Nordisk A/S via Thomson Reuters ONE